KCAS Bio will be attending NextGen Biomed 2026 in London, March 24–25, 2026. NextGen Biomed is a long-standing, community-driven platform that brings together the biologics and immunotherapy ecosystem to foster interdisciplinary collaboration and knowledge sharing across the R&D lifecycle.
Supporting Biologics Drug Development
KCAS Bio supports biologics drug development across preclinical and clinical stages with integrated bioanalytical and biomarker solutions. Our capabilities include support for advanced modalities such as antibody–drug conjugates, cell and gene therapies, bispecific antibodies, and targeted protein degraders, with expertise in pharmacokinetics, biomarkers, immunogenicity, and advanced flow cytometry to enable robust, decision-ready data.
Connect with KCAS Bio in London
We invite you to connect with KCAS Bio to discuss how our bioanalytical expertise can support your research and development programs. Whether you are addressing technology transfer challenges, advancing complex modalities, or preparing for clinical development, our teams are ready to support your objectives.
Contact us to schedule a meeting.